

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/130136 A1

(51) International Patent Classification:
A61K 31/404 (2006.01) *A61P 25/30* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2021/061506

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
09 December 2021 (09.12.2021)

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(30) Priority Data:
63/125,181 14 December 2020 (14.12.2020) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH). **YALE UNIVERSITY** [—/US]; Two
Whitney Avenue, New Haven, Connecticut 06510 (US).

(72) Inventors: **GASPARINI, Fabrizio**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **GOMEZ-MANCILLA, Bal-
tazar**; Novartis Pharma AG, Postfach, 4002 Basel (CH).
KRYSTAL, John; Department of Psychiatry at the Yale
School of Medicine, 300 George Street, New Haven, Con-
necticut 06511 (US). **MALATERRE, Vincent**; Novartis
Pharma AG, Postfach, 4002 Basel (CH). **O'MALLEY,
Stephanie**; Department of Psychiatry at the Yale School
of Medicine, 300 George Street, New Haven, Connecticut
06511 (US). **PEARLSON, Godfrey**; Department of Psy-
chiatry at the Yale School of Medicine, 300 George Street,
New Haven, Connecticut 06511 (US). **POTENZA, Marc**;
Department of Psychiatry at the Yale School of Medicine,
300 George Street, New Haven, Connecticut 06511 (US).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse
35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER

(57) Abstract: The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.

WO 2022/130136 A1